Faeth Therapeutics (FTH) Accounts Payables (2020 - 2026)

Faeth Therapeutics (FTH) has reported Accounts Payables for 7 consecutive years, with $7.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 567.22% year-over-year to $7.6 million; the trailing twelve-month figure through Jun 2026 stood at $7.6 million (up 567.22% YoY), and the FY2025 full-year result was $1.5 million, up 18.67% from the prior year.
• Accounts Payables slipped to $7.6 million in Q2 2026 per FTH's latest filing, from $9.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $9.0 million in Q1 2026 and bottomed at $1.1 million in Q2 2025.
• Historically, Accounts Payables has averaged $3.2 million across 5 years, with a median of $2.3 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Accounts Payables plunged 62.13% in 2023, then surged 567.22% in 2026.
• Over 5 years, Accounts Payables stood at $4.5 million in 2022, then slumped by 62.13% to $1.7 million in 2023, then fell by 26.33% to $1.2 million in 2024, then grew by 18.67% to $1.5 million in 2025, then soared by 411.34% to $7.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $7.6 million, $9.0 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.